TOP > 外国特許検索 > ANTICANCER AGENT

ANTICANCER AGENT

外国特許コード F130007631
整理番号 AF12-12WO
掲載日 2013年9月30日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2013JP055927
国際公開番号 WO 2013133253
国際出願日 平成25年3月5日(2013.3.5)
国際公開日 平成25年9月12日(2013.9.12)
優先権データ
  • 特願2012-052334 (2012.3.8) JP
発明の名称 (英語) ANTICANCER AGENT
発明の概要(英語) The present invention provides an anticancer agent for which an active ingredient is a human antibody light chain exhibiting cytotoxicity against cancer cells, in particular lung cancer cells. This anticancer agent is characterized by primarily containing either: a human antibody κ-type light chain that is a dimer and comprises a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO: 1, 9, or 13, or by an amino acid sequence obtained when one or a plurality of amino acids are substituted, added, or deleted within those amino acid sequences; or a human antibody κ-type light chain that is a monomer and comprises a polypeptide in which a variable region is represented by an amino acid sequence of SEQ ID NO: 19 or by an amino acid sequence obtained when one or a plurality of amino acids are substituted, added, or deleted within that amino acid sequence.
従来技術、競合技術の概要(英語) BACKGROUND ART
Antibodies, heavy chain and light chain (H chain: Heavy chain) (L chain: Light chain) configured from. The heavy chain and light chain, variable region (VR: Variable Region) and a constant region derived from a (CR: Constant Region) and, the variable region, hypervariable region (CDR: Complementarity Determining Region) has. Further, the light chain of the antibody, and classified into λ κ type.
In recent years, the antibody with the enzyme-like activity, i.e., antibody enzyme is attracting attention. Antibody enzyme, enzymatically active antibody and has both high molecular recognition ability for, medical, chemical industry, such as in the food industry, and a method of manufacturing are expected to be applied. In particular, high specificity to the target molecule, and cytotoxic for a target molecule by the enzymatic activity can be achieved in the antibody enzyme, superior anti-cancer agent and with fewer side effects is expected.
The present inventors have, heretofore, various of the inventive antibody to an enzyme has been studies were performed to determine (for example, see Patent Document 1). Conventional, fully human antibodies with the enzyme sequence, obtained from multiple myeloma patients other than (BJP) could not be obtained. Reduced the number of patients with multiple myeloma patients, and has less BJP enzyme activity, human-type antibody was difficult to acquire an enzyme. However, the enzyme is a human antibody, fewer side effects upon administration to a human body is expected to be of the order, and the like pharmaceutical companies abroad, useful to develop a human antibody in the enzyme .
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • UDA Taizo
  • HIFUMI Emi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
参考情報 (研究プロジェクト等) CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close